Literature DB >> 8974050

Heart glycogen content and isoprenaline-induced myocardial lesions.

M Mráz1, S Hynie.   

Abstract

The role of glycogen content in the heart for the development of isoprenaline-induced myocardial lesions (IML) was studied in Wistar rats and in two inbred rat strains: In IR rats (resistant to the development of IML) and in IS rats (sensitive to IML development). Glycogen content in the heart can be dramatically lowered or increased by various interventions. IML develop during the period of very low heart glycogen content (about 0.6 mg.g-1) induced by isoprenaline administration. In animals with increased resistance to IML, either due to genetic factors or induced by isoprenaline pretreatment a high glycogen content in the heart is found (up to 7.5 mg.g-1). The increase of resistance to IML development and increased glycogen content induced by isoprenaline pretreatment were accompanied by lower basal or ISO-, guanylylimidodiphosphate- (Gpp/NH/p) and forskolin-stimulated activities of adenylyl cyclase. On the other hand, these parameters did not differ between IR and IS rats in spite of the presence of significant differences in the resistance to the development of IML and in heart glycogen content in these two rats strains. These results suggest that genetically determined differences between two inbred rat strains in the resistance of the heart to the development of IML and in the heart glycogen content are caused by factors which are independent of the receptor-adenylyl cyclase complex and are therefore different from those involved in the increase of resistance and glycogen content due to isoprenaline pretreatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8974050     DOI: 10.1007/bf00408651

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  14 in total

1.  The determination of glycogen in liver and muscle by use of anthrone reagent.

Authors:  N V CARROLL; R W LONGLEY; J H ROE
Journal:  J Biol Chem       Date:  1956-06       Impact factor: 5.157

2.  Genetic differences in the resistance of rats to isoprenaline-induced heart lesions.

Authors:  M Mráz; E Faltová; D Lincová; J Sedivý; N Gaier; E Mühlbachová; M Cernohorský; A Vrána
Journal:  Basic Res Cardiol       Date:  1986 Jan-Feb       Impact factor: 17.165

3.  The role of myocardial glycogen content for the development of isoprenaline-induced myocardial lesions in different inbred strains of rats.

Authors:  M Mráz; V Kren; D Krsiaková; A Vrána; S Hynie
Journal:  Basic Res Cardiol       Date:  1995 Nov-Dec       Impact factor: 17.165

4.  The glucose-insulin-potassium (GIK) regimen in the treatment of myocardial ischemia.

Authors:  N Brachfeld
Journal:  Circulation       Date:  1973-09       Impact factor: 29.690

Review 5.  The mechanism of myocyte death in ischaemia.

Authors:  L H Opie
Journal:  Eur Heart J       Date:  1993-11       Impact factor: 29.983

Review 6.  Arrhythmogenic amphiphilic lipids and the myocardial cell membrane.

Authors:  P B Corr; R W Gross; B E Sobel
Journal:  J Mol Cell Cardiol       Date:  1982-11       Impact factor: 5.000

Review 7.  Influence of free fatty acids on myocardial oxygen consumption and ischemic injury.

Authors:  H Vik-Mo; O D Mjøs
Journal:  Am J Cardiol       Date:  1981-08       Impact factor: 2.778

8.  Protective effect of isoprenaline pretreatment on the cardiotoxic effect of the same drug.

Authors:  E Faltová; M Mráz; J Sedivý
Journal:  Physiol Bohemoslov       Date:  1983

9.  Myocardial protection during ischemic cardiac arrest. Possible deleterious effects of glucose and mannitol in coronary infusates.

Authors:  D J Hearse; D A Stewart; M V Braimbridge
Journal:  J Thorac Cardiovasc Surg       Date:  1978-07       Impact factor: 5.209

10.  An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts.

Authors:  G D Lopaschuk; R B Wambolt; R L Barr
Journal:  J Pharmacol Exp Ther       Date:  1993-01       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.